Table 1

Patient demographics at time of biopsy

Total cases*138100
Age, years
ICI therapy
  Plus chemotherapy107.25
  Plus targeted therapy128.70
  Plus chemotherapy10.72
  • *Includes 127 unique patients.

  • †Other malignancies: squamous cell carcinoma of the head and neck (6), primary neurologic (4), sarcoma (3), small-cell lung cancer (3), endocrine (2), gastrointestinal (1), mesothelioma (1).

  • CTLA-4, cytotoxic T lymphocyte antigen-4; ICI, immune checkpoint inhibitor; NSCLC, non-small cell lung cancer; PD-1/PD-L1, programmed cell death 1/programmed cell death ligand 1.